v3.26.1
Significant Agreements - Additional Information (Details1)
Mar. 31, 2026
USD ($)
Affini-T Therapeutics, Inc. | Development, Option and License Agreement  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Transaction price allocated to remaining performance obligations $ 0
Ionis | Collaboration and License Agreement  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Transaction price allocated to remaining performance obligations $ 15,100,000
Ionis | Collaboration and License Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-04-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 9 months
Ionis | Collaboration and License Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Ionis | Collaboration and License Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year